secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xencor Inc (XNCR)
CIK:        0001326732
Form:       8-K
Filed at:   2022-11-07T23:59:59+00:00
Accession:  0001558370-22-016645
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xencor Q3 net loss $32.8M ($0.55/sh); XmAb564 shows durable Treg expansion in Phase 1a
--------------------------------------------------------------------------------

- Q3 revenue $27.3M (up from $19.7M); net loss $32.8M vs $40.2M loss year ago.
- Cash $654.6M; funding through 2025; year-end 2022 cash guided at $575-600M.
- XmAb564 Phase 1a: single-dose well-tolerated; 117-fold peak CD25 bright Treg expansion; Phase 1b in atopic dermatitis/psoriasis started.
- Vudalimab Phase 2 in mCRPC; plamotamab Phase 2 enrolling; data at SITC and ASH.
- Vir royalty $17.8M in Q3; Zenas raised $118M, plans Phase 3 for obexelimab.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1326732/000155837022016645/0001558370-22-016645-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1326732/000155837022016645/xncr-20221107x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-22-016645

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer